Elritercept
TAK-226-3001
Phase 3 small_molecule active
Quick answer
Elritercept for Myelodysplastic Syndrome is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Myelodysplastic Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active